Cargando…
TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model
BACKGROUND: Osteosarcoma (OS) is the most common primary malignant bone tumour. Unfortunately, no new treatments are approved and over the last 30 years the survival rate remains only 30% at 5 years for poor responders justifying an urgent need of new therapies. The Mutt homolog 1 (MTH1) enzyme prev...
Autores principales: | Moukengue, Brice, Brown, Hannah K, Charrier, Céline, Battaglia, Séverine, Baud'huin, Marc, Quillard, Thibaut, Pham, Therese M, Pateras, Ioannis S, Gorgoulis, Vassilis G, Helleday, Thomas, Heymann, Dominique, Berglund, Ulrika Warpman, Ory, Benjamin, Lamoureux, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063190/ https://www.ncbi.nlm.nih.gov/pubmed/32151797 http://dx.doi.org/10.1016/j.ebiom.2020.102704 |
Ejemplares similares
-
Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
por: Lallier, Morgane, et al.
Publicado: (2021) -
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020) -
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors
por: Jacques, Camille, et al.
Publicado: (2016) -
Origin and Therapies of Osteosarcoma
por: Moukengue, Brice, et al.
Publicado: (2022) -
Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma
por: Georges, Steven, et al.
Publicado: (2018)